Disclose full safety and efficacy data from the first two cohorts
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 17 Dec 2021
- Due
- 30 Jun 2023
- Delivered
- 21 Jun 2023
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Full safety and efficacy data from the first two cohorts in the Phase I/II clinical trial are expected in the first half of 2023”
What we found
Evidence strength A What the grades mean
The company announced interim data from the Phase I/II clinical trial of AMT-130, including safety and efficacy information from the initial cohorts, on June 21, 2023, meeting the first-half 2023 deadline.
-
A uniQure N.V. 10-Q filed 2023-11-07
“On June 21, 2023, we announced interim data, including up to 24-month follow-up, from 26 patients enrolled in the ongoing U.S. Phase I/II clinical trial of AMT-130.” ✓ confirmed on the page
Market reaction: the shares moved +2.7% against the S&P 500 over the three sessions around the disclosure (6 Nov 2023 to 9 Nov 2023). What this measures
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Disclose
- Deliverable
- full safety and efficacy data
- Where
- United States
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
- Conditional
- Yes: after all patients in the higher-dose cohort have achieved one year of follow-up
- Depends on
- Customer, Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you uniQure N.V.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-QURE-001788 · Corrections policy